New CSF Biomarkers for Alzheimer's Disease
Recruiting · NCT03621839 · Observational (researchers observe without assigning treatment) · Lead sponsor: Central Hospital, Nancy, France
View the official record on ClinicalTrials.gov →What this trial is about
Today, the Alzheimer's disease (AD) diagnosis is founded not only on clinical criteria but also on complementary examinations to confirm a physiopathological process of AD. In complex cases, lumbar punction could be necessary in order to measure Aβ peptides and Total and phosphorylated Tau but new biomarkers could be useful. The main objective of this project is to conserve these cerebrospinal fluids, collected in usual practice in order to validate new biomarkers for diagnosis, prognosis or therapeutic following of Alzheimer's disease and other dementia.
Who can take part
Age range
No age limits stated
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Lumbar punction collected in usual practice in the context of dementia diagnosis
Exclusion criteria
- Absence of consent
Where it is running
1 location listed.
- CHRU De Nancy - Nancy, Grand Est, France